



GP 1642/10



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Rosenblum *et al.* § ART UNIT: 1642  
§  
FILED: January 7, 1999 §  
§  
SERIAL NO.: 09/226,895 § EXAMINER:  
§ K. Canella  
§  
FOR: Potentiation of §  
Anti-CD38-Immunotoxin § DOCKET: D6205

The Assistant Commissioner of Patents and Trademarks  
BOX NON-FEE AMENDMENT  
Washington, DC 20231

RECEIVED

SEP 13 2000

CERTIFICATE OF MAILING UNDER 37 CFR 1.8 TECH CENTER 1600/2900

Dear Sir:

I hereby certify under 37 CFR 1.8 that the following correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to Commissioner of Patents and Trademarks, Washington DC 20231.

- 1) Response to Office Action (8 Pages);
- 2) Petition for Extension of Time (3 Months); and,
- 3) Check (\$435) and return postcard.

Please return the enclosed postcard acknowledging receipt of this correspondence.

Respectfully submitted,

Date: Sept 1, 2000  
McGREGOR & ADLER, LLP  
8011 Candle Lane  
Houston, Texas 77071  
(713) 777-2321  
badler1@houston.rr.com

Benjamin Aaron Adler  
Benjamin Aaron Adler, Ph.D., J.D.  
Counsel for Applicant  
Registration No. 35,423



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
SEP 13 2000

APPLICANT: Rosenblum *et al.*

§

ART UNIT: 1642

§

FILED: January 7, 1999

§

SERIAL NO.: 09/226,895

§

EXAMINER:

§

K. Canella

§

FOR: Potentiation of

§

Anti-CD38-Immunotoxin

§

DOCKET: D6205

The Assistant Commissioner of Patents and Trademarks

BOX NON-FEE AMENDMENT

Washington, DC 20231

RESPONSE UNDER 37 C.F.R. § 1.111

#66A  
LCD  
9/14/20

Dear Sir:

In response to the Office Action mailed March 2, 2000, please enter the following amendments and remarks. Reconsideration of the pending claims as amended is respectfully requested.

IN THE CLAIMS:

Please amend claim 1 as follows:

1. A method of treating an individual having a pathophysiological state selected from the group consisting of acute myeloid leukemia, acute promyelocytic leukemia, lymphomas, and myelomas, comprising the steps of:

A